DEK Vaccines Limited
Vaccines Fill & Finish Project in Accra, Ghana

COMPANY PROFILE

AVMI - ETHIOPIA. JUNE, 16, 2023
a. Who we are, & what we do

• The DEK Vaccines Limited is a vaccines manufacturing factory starting with fill and finish and eventually expanding into vaccine manufacturing and production.
• DEK is equipped with two production lines 1. Liquid vial filling line and 2. Oral Vaccines filling Line. Over time, the project will involve building a total of four fill and finish lines that have the capacity to produce 600 Million doses of various vaccines per annum.
• Using new age state of the art technology, the fill and finish facility DEK have the capability to fill both mRNA and traditional vaccines. All production suites at DEK have BSL-2, GMP environment with Isolator technology to make sure all type of vaccines could be produced.
• DEK founder has unique and deep experience of the African healthcare industry, having setup and run one of Ghana’s largest pharmaceutical companies that sells medicine in over 11 countries in West Africa. Dr Kofi Nsiah-Poku, founder and CEO of DEK, founded Kinapharma in 1996. Kinapharma manufactures and sells over 150 drugs ranging from generics to over the counter and branded ethical products, to over 11 countries in Africa.
• DEK completed its bankable feasibility study in 2022 and in coming investors benefit from investigating in the project that is ready to start manufacturing. Sponsors have invested 11% along with a grant of 5% adding to 16% already invested in the project with incoming investors from Europe and Africa.
• DEK Ground breaking ceremony was held by His Excellency the President of Ghana. The project is located at Kotoku road, off Accra Nsawam road
• Initially focus on providing fill and finish services for Malaria, HPV, Pentavalent and Oral Cholera vaccines through two production lines
• A US$158 million facility, with capacity for 600 million doses vaccines per annum to align the WHO objectives of Preparedness for Pandemic.
• Working arrangements in place with Bulk formulate suppliers
• Construction of DEK civil building has started with ground breaking ceremony, it is estimated to complete civil construction by 2nd QTR 2024, to complete the project by 2025.
• The project has the strong support and backing of the Government of Ghana through the National Vaccine Institute
### b. What are we offering

**DEK Vaccines Limited**  
**A project in Accra, Ghana**  
**To manufacture vaccines by Fill & Finish Technology**  

**158 Million USD project to produce 600 Million Doses of 13 vaccines in Africa**

<table>
<thead>
<tr>
<th>Key Features</th>
<th>Preparedness for Pandemic</th>
<th>Fulfilling African Need of Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>R21 Malaria Vaccine</td>
<td>600 Million doses capacity to be manufactured under BSL-2, GMP facility with isolators ensures the production capability of multiple products once needed at DEK factory.</td>
<td>Emerging products such as those for Lassa fever, malaria, and COVID-19 could find substantial demand in coming years, depending on ongoing need and, for products still in development, licensure and eventual commercial marketing</td>
</tr>
<tr>
<td>HPV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentavalent Vaccine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cholera Vaccine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- DEK will be the first company to manufacture R21 Malaria vaccine in Africa.
- DEK aims to manufacture 12 vaccines in its facility.
- The first 4 vaccines (Malaria, HPV, Pentavalent and OPV to be manufactured by 2025
- R21, HPV and OCV are expected to fulfill the 100% demand of Africa
c. What we are looking for

DEK Vaccines Limited
Is looking for:

1. Funds to have Financial Close
2. Advance Purchase Guarantee
3. Recognition in Continent
4. Introduction to Bulk Vaccine Manufactures

**99 Million fund raise to have Financial Close of Phase 1**

- DEK Bankable feasibility by BCG suggests that DEK need USD158M to complete the installation of 4 production lines
- DEK is looking for potential investors and grant funds to achieve the financial close
- DEK immediate need is 98 Million USD to complete the phase 1 to manufacture Malaria, HPV, Pentavalent and OCV vaccines

**Recognition / APG**

- DEK is building a 600 Million doses capacity project.
- GAVI, UNICEF, AU-PPM need to recognize the DEK capacity to align with the future demand of African manufactured
- Advance Purchase Guarantee will be key factor in securing the funds from the leading financial institutions

**Formulated Bulk**

- PAVM, AVMI to bring the interested bulk manufactures to introduce DEK and other upcoming manufacturers for technical evaluation
- Upon the successful contract for the supply of formulated bulk to DEK PAVM & AVMI should have a mechanism to assure that GAVI, UNICEF and AU-PPM take DEK contract in their future procurement plan.
Pharm. Dr Kofi Nsiah-Poku  
**DEK Managing Director**  
**CEO, Kinapharma**  
+233 24 431 4174  
knpoku@kinapharma.com

Farhan Ahmad Khan  
**Project Manager**  
C/o +233 20 797 7922  
farhan@kinagroupltd.com

www.dekvaccines.com